Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Top Cited Papers
- 28 January 2021
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 384 (4), 325-334
- https://doi.org/10.1056/nejmoa2008470
Abstract
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear.Keywords
Funding Information
- United Therapeutics Corporation
This publication has 16 references indexed in Scilit:
- Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisRespiratory Medicine, 2015
- Use of Pulmonary Arterial Hypertension–Approved Therapy in the Treatment of Non–Group 1 Pulmonary Hypertension at US Referral CentersPulmonary Circulation, 2015
- Inhaled Treprostinil in Group-3 Pulmonary HypertensionThe Journal of Heart and Lung Transplantation, 2015
- Pulmonary Hypertension due to Lung Disease and/or HypoxiaClinics in Chest Medicine, 2013
- Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonistBiochemical Pharmacology, 2012
- Six-Minute-Walk Test in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2010
- Iloprost Improves Gas Exchange and Exercise Tolerance in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary DiseaseRespiration, 2009
- Pulmonary hypertension in interstitial lung diseaseInternational Journal of Clinical Practice, 2008
- The distance-saturation product predicts mortality in idiopathic pulmonary fibrosisRespiratory Medicine, 2006